Antidepressants During Pregnancy: New Research Says Untreated Depression Is the Real Risk

Stopping antidepressants during pregnancy feels like the responsible choice. New research says it is often the most dangerous one. A Monash University study following 149 mothers and their children for eight years found that untreated depression during pregnancy doubled the odds of childhood anxiety by age four. A JAMA Psychiatry review from Children's National Hospital and Harvard says treatment should be prioritized, full stop. The fear around medication is understandable. The evidence says the fear is wrong.

Why Traditional Methods Fail

The standard advice given to pregnant women with depression is some version of "talk to your doctor." That sounds reasonable until you realize what actually happens next. Women Google "antidepressants during pregnancy" at midnight. They find forum threads about birth defects and withdrawal symptoms. They arrive at their next appointment having already decided to stop. Their doctor may not have the latest data. The conversation lasts seven minutes. The prescription goes unfilled.

One in five pregnant women experiences depression or anxiety. Research consistently shows that the vast majority discontinue medication either before conception or as soon as they see a positive test. A 2024 meta analysis in Contemporary OB/GYN found that adolescent oral contraceptive users had a small but measurable link to future depression. The anxiety around reproductive psychiatric medication is so culturally entrenched that women are making medical decisions based on fear rather than evidence.

This happens for a specific reason. Pregnancy feels like a high stakes environment where any intervention seems risky and doing nothing seems safe. But depression is not nothing. It is an active medical condition with measurable effects on fetal development, maternal health, and child outcomes. The Monash study makes this explicit. Children whose mothers had untreated depression during pregnancy were twice as likely to meet criteria for an anxiety disorder at age four. The untreated depression was the intervention with side effects.

The Cognitive Architecture of the Problem

Here is what the new research actually shows, and why it matters.

The Monash Longitudinal Study (Psychoneuroendocrinology, 2026). Professor Megan Galbally, director of the Centre for Women's and Children's Mental Health at Monash University, followed 149 pregnant women with depression for eight years. Some continued antidepressants. Some did not. The findings were striking:

• Untreated maternal depression during pregnancy was associated with double the odds of a child having an anxiety disorder at age four.
• Treating maternal depression led to a measurable reduction in depression and anxiety in children at age four, and in girls, the protective effect persisted to age eight.
• No major developmental differences were found between children whose mothers took antidepressants and those whose mothers did not.
• Cortisol markers measured in the placenta, maternal hair postpartum, and infant saliva at twelve months predicted anxiety onset in girls, suggesting biological stress pathways that depression keeps open.

For eight year old boys, the primary predictor of anxiety was current maternal depression. In other words, if mom was still depressed, the child felt it. The treatment she received during pregnancy mattered less than whether she stayed well.

The JAMA Psychiatry Special Communication (August 2026). Researchers from Children's National Hospital, George Washington University, University of British Columbia, Weill Cornell, Brigham and Women's Hospital, and Harvard Medical School published a landmark review. Their conclusion was unambiguous: treatment of perinatal major depressive disorder should be prioritized during pregnancy. They argued that expanding access to maternity, child health, and psychiatric care is a public health imperative, and that structured, evidence based decision making can help clinicians and patients balance the risks of untreated depression, treatment benefits, and potential risks associated with SSRI exposure.

The Postpartum Depression Context. The Healthcare MDPI study from July 2026 found that 29.4 percent of mothers meet criteria for postpartum depression at six weeks postpartum. Only 2 to 3 out of every 100 postpartum women with depression receive adequate treatment. When you stop antidepressants during pregnancy, you are not preventing a problem. You are removing a treatment from a system that is already catastrophically undertreating the condition it exists for.

The Lindsay Clancy Trial. As the Clancy murder trial brings postpartum psychosis into national headlines this week, the cultural conversation around maternal mental health has never been more visible. The lesson from that case is not that mothers are dangerous. It is that untreated maternal mental illness is dangerous. The women who needed medication and did not get it, or stopped it, are the ones the system failed.

The AlphaMa Solution: Moving the Burden

The problem is not that women do not know what to do. The problem is that the cognitive labor of weighing risks and benefits, tracking symptoms, coordinating between an OB and a psychiatrist, and making these decisions alone at midnight is itself a health risk. It is the same mental load that defines modern motherhood, now with clinical stakes.

This is where the model has to change. The decision about whether to continue psychiatric medication during pregnancy should not rest entirely on a mother's shoulders. It should be supported by proactive screening, integrated care teams, and tools that help track symptoms over time rather than asking women to report them in a seven minute appointment.

AlphaMa is built on the principle that maternal mental health should be monitored continuously and proactively, not reactively. The same way an OB tracks fetal growth, someone should be tracking how mom is doing. Not through a single screening at six weeks postpartum. Through the whole arc. Because the Monash data shows that the effects of untreated depression ripple forward for eight years and counting, and the JAMA Psychiatry review confirms that this is a systemic failure, not an individual one.

If you are pregnant and taking antidepressants, the research says talk to your doctor. But now you have data to bring to that conversation. The risk of stopping is no longer hypothetical. It has been measured.